ATN-161

1 1

Selleck Chemicals

S8454-5MG

€144,00 EUR
€144,00 EUR
Sale Sold out
Taxes included. Shipping calculated at checkout.
Size
View full details

ATN-161 is an antagonist of Integrins used in studies of target-focused biology. In practice, this places the compound in experiments that measure annotated target biology and downstream cellular responses in angiogenesis and cancer models.

By blocking Integrins, ATN-161 can be used to examine annotated target biology and downstream cellular responses. That positioning is consistent with receptor-blockade and ligand-competition studies and with follow-up studies that compare concentration-dependent responses across orthogonal assay formats. In angiogenesis and cancer models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

  • Target-focused assays involving Integrins
  • Receptor-blockade and ligand-competition studies
  • Phenotypic profiling in angiogenesis and cancer models
  • Combination studies with orthogonal perturbagens

Overall, ATN-161 is appropriate when a defined chemical perturbant is needed to connect Integrins with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in angiogenesis and cancer models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.

Targets:
Integrins
Target Class:
Other
Research Area:
Angiogenesis • Cancer
CAS No.:
262438-43-7
Molecular Weight:
597.64
Formula:
C₂₃H₃₅N₉O₈S
SMILES:
CC(=O)N1CCCC1C(=O)NC(CC2=CN=CN2)C(=O)NC(CO)C(=O)NC(CS)C(=O)NC(CC(=O)N)C(=O)N
InChIKey:
MMHDBUJXLOFTLC-UHFFFAOYSA-N
PubChem:
9960285
Storage Temperature:
-20°C

For Research Use Only. Not intended for diagnostic or therapeutic use.
Products may be subject to intellectual property rights.

The purchase of this product does not grant any license for commercial use, manufacturing, or clinical applications. The user is responsible for ensuring compliance with applicable laws and third-party rights.